@BrundinPatrik @ccbpstudy We are developing assays of selected drugs with putative neuroprotective effects (in animal models; failed in trials) to match these drugs with those in the population whose assay values render them candidates for them (individual
@DrAlfonsoFasano @wojla @ArjBalachandar @andrea_sturchio @LucaMarsili1 I don’t know exactly how but the idea that clinicians can continue setting the gold standard (“truth”) is becoming hard to justify. This is what inspired our agnostic, exploratory study
@BrundinPatrik @RichelleFlan @MeganDuffyPhD @ElfarrashSara @Hlashuel @MaluTansey @SamirKMaji1 @Neuronologist1 @verbeeldingskr8 @endingpdbook We will deploy bioassays of drugs already available and considered "neuroprotective" at the time of their clinical
RT @Neuronologist1: The CCBP methods paper is finally here! Imho, this is what is needed if we are ever going to understand ourselves, our…